Valuation: Exact Sciences Corporation

Market Cap 20.03B 17.5B 16.19B 14.85B 28.11B 1,930B 28.6B 193B 75.84B 942B 75.21B 73.55B 3,253B P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 21.6B 18.88B 17.46B 16.02B 30.32B 2,081B 30.85B 208B 81.79B 1,016B 81.1B 79.32B 3,508B EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
1 day+0.95%
6 months+2.51%
Current year+3.30%
Current year 101.51
Extreme 101.51
104.98
1 year 38.81
Extreme 38.8118
104.98
3 years 38.81
Extreme 38.8118
104.98
5 years 29.27
Extreme 29.27
119.36
10 years 11.96
Extreme 11.96
159.54
Date Insider Type Main position Quantity % Market Cap.
23/03/26 Issuer sale

Director

28,899 0.0151%
23/03/26 Issuer sale

Director

20,558 0.0108%
23/03/26 Issuer sale

Director

17,169 0.0090%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+97.98%+8.30% 20.03B
-0.49%+5.52%+134.63%+105.55% 4.75B
-3.49%+9.62%+99.82%+208.23% 3.67B
+1.77%+10.87%-25.08%-35.72% 2.12B
-1.69%+8.88%+140.21%-39.95% 2.12B
+35.60%+46.42%+112.20%+312.90% 1.54B
+0.71%+23.09%+173.75%-44.57% 1.04B
-2.39%+1.06%-11.61%+37.26% 894M
+5.64%+11.23%-30.48%-8.55% 507M
-3.06%+4.84%+5.11% - 490M
Average -0.45%+7.98%+69.65%+60.38% 3.71B
Weighted average by Cap. +0.01%+3.07%+95.32%+47.31%

Financials

2024 2025
Net sales 2.76B 2.41B 2.23B 2.05B 3.87B 266B 3.94B 26.6B 10.45B 130B 10.36B 10.13B 448B 3.25B 2.84B 2.62B 2.41B 4.56B 313B 4.64B 31.3B 12.3B 153B 12.19B 11.93B 527B
Net income -1.03B -899M -832M -763M -1.44B -99.14B -1.47B -9.92B -3.9B -48.41B -3.86B -3.78B -167B -208M -182M -168M -154M -292M -20.04B -297M -2B -788M -9.79B -781M -764M -33.78B
Net Debt 1.74B 1.52B 1.4B 1.29B 2.44B 167B 2.48B 16.75B 6.58B 81.77B 6.53B 6.38B 282B 1.57B 1.37B 1.27B 1.16B 2.2B 151B 2.24B 15.14B 5.95B 73.88B 5.9B 5.77B 255B
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
  1. Stock Market
  2. Stocks
  3. EXAS Stock